Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38594748)

  • 21. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
    Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
    Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MCM5 as a target of BET inhibitors in thyroid cancer cells.
    Mio C; Lavarone E; Conzatti K; Baldan F; Toffoletto B; Puppin C; Filetti S; Durante C; Russo D; Orlacchio A; Di Cristofano A; Di Loreto C; Damante G
    Endocr Relat Cancer; 2016 Apr; 23(4):335-47. PubMed ID: 26911376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual inhibition of COX-2/5-LOX blocks colon cancer proliferation, migration and invasion in vitro.
    Che XH; Chen CL; Ye XL; Weng GB; Guo XZ; Yu WY; Tao J; Chen YC; Chen X
    Oncol Rep; 2016 Mar; 35(3):1680-8. PubMed ID: 26707712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of novel small compounds that restore E-cadherin expression and inhibit tumor cell motility and invasiveness.
    Hirano T; Satow R; Kato A; Tamura M; Murayama Y; Saya H; Kojima H; Nagano T; Okabe T; Fukami K
    Biochem Pharmacol; 2013 Nov; 86(10):1419-29. PubMed ID: 24035834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LncRNA-ATB mediated E-cadherin repression promotes the progression of colon cancer and predicts poor prognosis.
    Yue B; Qiu S; Zhao S; Liu C; Zhang D; Yu F; Peng Z; Yan D
    J Gastroenterol Hepatol; 2016 Mar; 31(3):595-603. PubMed ID: 26487301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation.
    Li M; Yang J; Zhang L; Tu S; Zhou X; Tan Z; Zhou W; He Y; Li Y
    J Exp Clin Cancer Res; 2019 May; 38(1):211. PubMed ID: 31118055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type.
    Tarantelli C; Cannas E; Ekeh H; Moscatello C; Gaudio E; Cascione L; Napoli S; Rech C; Testa A; Maniaci C; Rinaldi A; Zucca E; Stathis A; Ciulli A; Bertoni F
    Explor Target Antitumor Ther; 2021; 2(6):586-601. PubMed ID: 36046113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
    Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer.
    Hong CS; Sun EG; Choi JN; Kim DH; Kim JH; Ryu KH; Shim HJ; Hwang JE; Bae WK; Kim HR; Kim KK; Jung C; Chung IJ; Cho SH
    Cancer Sci; 2020 Sep; 111(9):3268-3278. PubMed ID: 32533590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
    Leal AS; Williams CR; Royce DB; Pioli PA; Sporn MB; Liby KT
    Cancer Lett; 2017 May; 394():76-87. PubMed ID: 28254412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells.
    Dessein AF; Stechly L; Jonckheere N; Dumont P; Monté D; Leteurtre E; Truant S; Pruvot FR; Figeac M; Hebbar M; Lecellier CH; Lesuffleur T; Dessein R; Grard G; Dejonghe MJ; de Launoit Y; Furuichi Y; Prévost G; Porchet N; Gespach C; Huet G
    Cancer Res; 2010 Jun; 70(11):4644-54. PubMed ID: 20460542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
    Bäumer S; Bäumer N; Appel N; Terheyden L; Fremerey J; Schelhaas S; Wardelmann E; Buchholz F; Berdel WE; Müller-Tidow C
    Clin Cancer Res; 2015 Mar; 21(6):1383-94. PubMed ID: 25589625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exosomal lncRNA PVT1/VEGFA Axis Promotes Colon Cancer Metastasis and Stemness by Downregulation of Tumor Suppressor miR-152-3p.
    Lai SW; Chen MY; Bamodu OA; Hsieh MS; Huang TY; Yeh CT; Lee WH; Cherng YG
    Oxid Med Cell Longev; 2021; 2021():9959807. PubMed ID: 34336125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Proteomics Analysis Identifies Cdc42-Cdc42BPA Signaling as Prognostic Biomarker and Therapeutic Target for Colon Cancer Invasion.
    Hu HF; Xu WW; Wang Y; Zheng CC; Zhang WX; Li B; He QY
    J Proteome Res; 2018 Jan; 17(1):265-275. PubMed ID: 29072916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.
    Lockwood WW; Zejnullahu K; Bradner JE; Varmus H
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19408-13. PubMed ID: 23129625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer.
    Sack U; Walther W; Scudiero D; Selby M; Kobelt D; Lemm M; Fichtner I; Schlag PM; Shoemaker RH; Stein U
    J Natl Cancer Inst; 2011 Jul; 103(13):1018-36. PubMed ID: 21685359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting BET proteins inhibited the growth of non-small cell lung carcinoma through downregulation of Met expression.
    Yuan T; Ni P; Zhang Z; Wu D; Sun G; Zhang H; Chen B; Wang X; Cheng Z
    Cell Biol Int; 2023 Mar; 47(3):622-633. PubMed ID: 36448366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal growth factor stimulation can substitute for c-Src overexpression in promoting breast carcinoma invasion.
    Lotz M; Wang HH; Cance W; Matthews J; Pories S
    J Surg Res; 2003 Feb; 109(2):123-9. PubMed ID: 12643853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
    Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.